🇺🇸 FDA
Patent

US 10933081

Myostatin iRNA compositions and methods of use thereof

granted A61KA61K31/712A61K31/7125

Quick answer

US patent 10933081 (Myostatin iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/712, A61K31/7125, A61K31/713, A61K9/0019